Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06445114 · ClinicalTrials.gov registry record · Phase 2
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
A Phase 2 study of Carcinoma and Oropharyngeal Cancer, sponsored by Zachary Zumsteg.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 4
- Study locations
NCT06445114 is a Phase 2 study of Carcinoma and Oropharyngeal Cancer that is actively recruiting participants, run by Zachary Zumsteg. The registered enrollment target is 50 participants, below the 253-participant average among 29 other Carcinoma trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT06445114, a Phase 2 study of Carcinoma and Oropharyngeal Cancer, is actively recruiting participants, sponsored by Zachary Zumsteg.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph nodes.
Conditions Studied
Interventions
- DRUG Cisplatin
Study Locations (4)
California
- Cedars-Sinai Cancer at Beverly Hills (THO) - Beverly Hills
- Cedars Sinai Medical Center - Los Angeles
- CS Cancer at Valley Oncology Medical Group - Tarzana
- CS Cancer at the Hunt Cancer Center - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2032-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06445114
The ClinicalTrials.gov registry entry for NCT06445114 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 253-participant average among 29 other Carcinoma trials with a reported enrollment target (80% lower). The listed sponsor is Zachary Zumsteg, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Cisplatin is the first listed.
NCT06445114 reports 4 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06445114 about?
NCT06445114 is a clinical study titled "Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer". This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph nodes.
What is the current status of trial NCT06445114?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-05-12. Estimated completion is 2032-06.
What conditions does trial NCT06445114 study?
This clinical trial studies the following conditions: Carcinoma, Oropharyngeal Cancer.
What interventions are being tested in trial NCT06445114?
The interventions under investigation include: Cisplatin (DRUG).
Who is sponsoring clinical trial NCT06445114?
This trial is sponsored by Zachary Zumsteg, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06445114 being conducted?
This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
RECRUITING · Phase 2
-
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
RECRUITING · Phase 2
-
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
COMPLETED · Phase 2
-
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
RECRUITING · Early Phase 1
-
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.